Dyronib 50mg (Dasatinib)

Contact us for more information
Wishlist Compare
Hetero Drugs Ltd

Dyronib 50mg (Dasatinib)

ManufacturerHetero Drugs LtdBrand nameDyronibInternational trade nameSprycelActive substanceDasatinibStrength50mgCategoryAnti Cancer

Description of Dyronib 50mg (Dasatinib 50mg)

Dyronib 50mg (Dasatinib 50mg) belongs to oral dual BCR/ABL and Src group of tyrosine kinase inhibitor approved for use in patients with chronic myelogenous leukaemia (CML). The main aim of Sprycel, are BCRABL, SRC, Ephrin’s and GFR.

Dyronib 50mg (Dasatinib 50mg) is a prescription medicine which used under the supervision of doctor.

Medical use /Indication of Dyronib 50mg (Dasatinib 50mg)

Dyronib 50mg (Dasatinib 50mg) is indicated for the treatment of adult patients having chronic myeloid leukaemia.

Dyronib 50mg (Dasatinib 50mg) is indicated for the treatment of adult patients having acute lymphoblastic leukaemia

Mechanism of Action Dyronib 50mg (Dasatinib 50mg)

Dasatinib is a group of medicine which belongs to protein tyrosine kinase inhibitor (TKI). Tyrosine kinases are proteins which work as chemical messengers to stimulate cancer cells to develop. Dasatinib inhibits the tyrosine kinases from passing chemical signals which tell the cells to develop.

Absorption of Dyronib 50mg (Dasatinib 50mg)

Not available

Distribution of Dyronib 50mg (Dasatinib 50mg)

volume of distribution 2505 L and plasma protein binding is 96%

Metabolism of Dyronib 50mg (Dasatinib 50mg)

Extensively metabolized in humans, mainly by the cytochrome P450 enzyme 3A4.

Excretion of Dyronib 50mg (Dasatinib 50mg)

Dasatinib excreted through the feces.

Half-life is 3-5 hours

Side effects of Dyronib 50mg (Dasatinib 50mg)

  • Skin rash
  • Infection
  • Nausea
  • Dyspnea
  • Anorexia
  • Arthralgia
  • Asthenia
  • Constipation
  • Dizziness
  • Musculoskeletal pain
  • Anemia
  • Febrile neutropenia
  • Thrombocytopenia
  • Mucosal inflammation
  • Diarrhea
  • Headache
  • Haemorrhage
  • Fatigue
  • Pyrexia

Precautions of Dyronib 50mg (Dasatinib 50mg)

Using of Dyronib 50mg (Dasatinib 50mg)  will results in Tumor lysis syndrome; maintain sufficient hydration and correct uric acid levels before to starting treatment

Dyronib 50mg (Dasatinib 50mg)  will causes Risk of fluid retention and pleural/pericardial effusion; manage with supportive care measures and/or dose modification

Myelosuppression which involves severe thrombocytopenia, neutropenia and Anemia may occurs; may manage by dose interference, dose reduction, or blocking of treatment; hematopoietic growth factor has been used with resistant myelosuppression

Advise females of reproductive possible to do not become pregnancy, which may contains the use of effective contraceptive methods, during treatment with Dyronib 50mg (Dasatinib 50mg)  and for 30 days after the final dose.

Certain patients with chronic phase CML and paediatric Ph+ ALL, reveals complete blood cell counts (CBCs) q2Weeks for 12 weeks, then q3Months thereafter, or as clinically indicated; show CBCs for the first 2 months weekly after that monthly,

Drug interaction of Dyronib 50mg (Dasatinib 50mg)

Dyronib 50mg (Dasatinib 50mg) concomitant use with CYP3A4 inhibitors will increase Dasatinib plasma concentration.

Dyronib 50mg (Dasatinib 50mg) combination with CYP3A4 inducers will reduces Dasatinib plasma concentration.

Dyronib 50mg (Dasatinib 50mg) combination with antacids will decrease Dasatinib plasma concentration.

Dyronib 50mg (Dasatinib 50mg) combination with H2 antagonists/proton pump inhibitors will decrease Dasatinib plasma concentration.

Dyronib 50mg (Dasatinib 50mg) Interaction with CYP3A4 substrates will have their plasma concentration altered by Dasatinib.

Pregnancy of Dyronib 50mg (Dasatinib 50mg)

Dyronib 50mg (Dasatinib 50mg) will cause fetal harm while using during pregnancy. Advise a pregnant woman of the possible risk to a foetus.

Lactation of Dyronib 50mg (Dasatinib 50mg)

Avoid breast feeding during Dyronib 50mg (Dasatinib 50mg) treatment

Dosage of Dyronib 50mg (Dasatinib 50mg)

Chronic Myeloid Leukaemia :

Dyronib 50mg (Dasatinib 50mg)  indicated for adults with Philadelphia chromosome-positive (Ph+) chronic myeloid leukaemia (CML) in chronic phase and Used for treatment of chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with support or intolerance to before therapy contains imatinib

Newly diagnosed

Starting dose with 100 mg PO qDay (morning or evening).

May raised to 140 mg qDay if insufficient response.

Advanced CML:

Starting dose with 140 mg PO qDay

May increase to 180 mg qDay if insufficient reactions

Acute Lymphoblastic Leukaemia :

Sprycel indicated for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukaemia (ALL) with resistance or intolerance to prior therapy

Initiate 140 mg PO qDay

May increase to 180 mg PO qDay if insufficient reactions.

Storage of Dyronib 50mg (Dasatinib 50mg)

Store at 20℃ to 25℃. Keep away from the children Use the medicine before expiry date Protect from direct sunlight. Discard the unused medicne by asking the advice from doctor or pharmacist.

Missed dose of Dyronib 50mg (Dasatinib 50mg)

In case of missed dose, patients must consult with medical oncologist and follow the regular dosing schedule.

Brand name:
International trade name:
Active substance:
Anti Cancer
Hetero Healthcare Ltd
60 Tablets
Product form:

No reviews found

Write feedback
Worldwide delivery

Our company ships from India to all countries of the world.

Genuine and Authentic products

All products supplied from the manufacturer of WHO : GMP certified facilities and ISO Certified facilitates

Economical and Affordable prices

All the products are supplying from manufacturing companies of India